Insulin resistance: Current concepts

Clinical Therapeutics

Volumn 20, Issue 2, 1998, Pages 216-231

  Bloomgarden, Zachary T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes mellitus; Impaired glucose tolerance; Insulin resistance; Metformin; Troglitazone

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; TROGLITAZONE;

ARTICLE; CORONARY RISK; DRUG MECHANISM; DYSLIPIDEMIA; FITNESS; GENETIC SUSCEPTIBILITY; GLUCOSE INTOLERANCE; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

EID: 0031799224     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80086-6     Document Type: Article

References (48)

1. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev. 1995;75:473-486.
2. Himsworth HP, Kerr RB. Insulin sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci. 1939;4:119.
3. Weir GC, Which comes first in non-insulin-dependent diabetes mellitus: Insulin resistance or beta-cell failure? Both come first. JAMA. 1995;273:1878-1879.
4. Hales CN. The pathogenesis of NIDDM. Diabetologia. 1994;37(Suppl 2):S162-S168.
5. Yki-Järvinen H. Pathogenesis of non-insulin-dependent diabetes. Lancet. 1994; 343:91-94.
6. Bloomgarden ZT. The etiology of type II diabetes, obesity, and the treatment of type II diabetes. Diabetes Care. 1996;19: 1317-1322.
7. Yki-Järvinen H. Glucose toxicity. Endocr Rev. 1992;13:415-431.
8. Randle PJ, Garland PB, Newsholme EA, Hales CN. The glucose fatty acid cycle in obesity and maturity onset diabetes mellitus. Ann NY Acad Sci. 1965;131:324-333.
9. Groop LC, Saloranta C, Shank M, et al. The role of free fatty acid metabolism in the pathogenesis of insulin resistance in obesity and non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1991;72:96-107.
10. Borkman M, Storlien LH, Pan DA, et al. The relation between insulin sensitivity and the fatty acid composition of skeletal muscle phospholipids. NEJM. 1993;328: 238-244.
11. Nuutila P, Raitakari M, Laine H, et al. Role of blood flow in regulating insulinstimulated glucose uptake in humans. Studies using bradykinin, [15O]water, and [18F]fluoro-deoxy-glucose and positron emission tomography. J Clin Invest. 1996; 97:1741-1747.
12. Nowicki M, Fliser D, Fode P, et al. Changes in plasma phosphate levels influence insulin sensitivity under euglycemic conditions. J Clin Endocrinol Metab. 1996;81:156-159.
13. Bloomgarden ZT, Ginsberg-Fellner F, Rayfield EJ, et al. Elevated hemoglobin A1c and LDL-cholesterol in thiazidetreated diabetics. Am J Med. 1984;77: 823-827.
14. Jacob S, Rett K, Wicklmayr M, et al. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: The carvedilol-metoprolol study. J Hypertens. 1996; 14:489-494.
15. Samuelsson O, Hedner T, Berglund G, et al. Diabetes mellitus in treated hypertension: Incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Goteborg, Sweden. J Hum Hypertens. 1994;8:257-263.
16. Del Prato S, Bonadonna RC, Bonora E, et al. Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. J Clin Invest. 1993;91:484-494.
17. Harris MI. Undiagnosed NIDDM: Clinical and public health issues. Diabetes Care. 1993;16:642-652.
18. Reaven GM, Brand RJ, Chen YD, et al. Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. Diabetes. 1993;42: 1324-1332.
19. Haffner SM. Risk factors for non-insulin-dependent diabetes mellitus. J Hypertens Suppl. 1995;13:S73-S76.
20. Harris MI. Epidemiologic studies on the pathogenesis of non-insulin-dependent diabetes mellitus (NIDDM). Clin Invest Med. 1995;18:231-239.
21. Porte D Jr, Kahn SE. The key role of islet dysfunction in type II diabetes mellitus. Clin Invest Med. 1995;18:247-254.
22. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus - A genetically programmed failure of the beta cell to compensate for insulin resistance. NEJM. 1996;334:777-783.
23. Zimmet PZ. Hyperinsulinemia - How innocent a bystander? Diabetes Care. 1993; 16(Suppl 3):56-70.
24. Dowse G, Zimmet P. The thrifty genotype in non-insulin dependent diabetes. BMJ. 1993;306:532-533. Editorial.
25. Yki-Järvinen H. Pathogenesis of non-insulin-dependent diabetes. Lancet. 1994; 343:91-94.
26. Williams B. Insulin resistance: The shape of things to come. Lancet. 1994;344: 521-524.
27. Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. NEJM. 1989;320:702-706.
28. Reaven GM. Syndrome X. Clin Diabetes. 1994;March/April:32-36.
29. Stern MP. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? Ann Intern Med. 1996; 124:110-116.
30. Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals: Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893-2899.
31. Ferrannini E. Syndrome X. Horm Res. 1993;39(Suppl 3):107-111.
32. Haffner SM, Miettinen H, Gaskill SP, et al. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes. 1995; 44:1386-1391.
33. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. NEJM. 1993;329: 1988-1992.
34. Pimenta W, Korytkowski M, Mitrakou A, et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in Type II diabetes: Evidence from studies in normal glucose tolerant individuals with a first degree NIDDM relative. JAMA. 1995;273: 1855-1861.
35. Martin BC, Warram JH, Krolewski AS, et al. Role of glucose and insulin resistance in development of Type 2 diabetes mellitus: Results of a 25-year follow up study. Lancet. 1992;240:925-929.
36. Banerji MA, Lebovitz HE. Insulin action in black Americans with NIDDM. Diabetes Care. 1992;15:1295-1301.
37. Bailey CJ, Turner RC. Metformin. NEJM. 1996;334:574-579.
38. Bailey C. Metformin - An update. Gen Phamtacol. 1993;24:1299-1330.
39. Sirtori CR, Pasik C. Re-evaluation of a biguanide. metformin: Mechanism of action and tolerability. Pharmacol Res. 1994;30:187-228.
40. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care. 1993;16:621-629.
41. UK Prospective Diabetes Study Group. Overview of 6 years' therapy of Type II diabetes: A progressive disease. Diabetes. 1995;44:1249-1258.
42. MacDougald OA, Lane MD. Transcriptional regulation of gene expression during adipocyte differentiation. Annu Rev Biochem. 1995;64:345-373.
43. Brun RP, Tontonoz P, Forman BM, et al. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 1996;10:974-984.
44. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisone proliferator-activated receptor-g. J Biol Chem. 1995;270:12953-12956.
45. Whitcomb RW, Saltiel AR. Thiazolidinediones. Expert Opin Invest Drugs. 1995; 4:1299-1309.
46. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. NEJM. 1994;331:1188-1193.
47. Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens. 1995;8:16-20.
48. Petrie JR, Donnelly J. New pharmacologic approaches to insulin and lipid metabolism. Drugs. 1994;47:701-710.